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Mammalian cells harbor more than a thousand RNA-
binding proteins (RBPs), with half of these employing
unknown modes of RNA binding. We developed
RBDmap to determine the RNA-binding sites of
native RBPs on a proteome-wide scale. We identi-
fied 1,174 binding sites within 529 HeLa cell
RBPs, discovering numerous RNA-binding domains
(RBDs). Catalytic centers or protein-protein interac-
tion domains are in close relationship with RNA-bind-
ing sites, invoking possible effector roles of RNA in
the control of protein function. Nearly half of the
RNA-binding sites map to intrinsically disordered
regions, uncovering unstructured domains as preva-
lent partners in protein-RNA interactions. RNA-bind-
ing sites represent hot spots for defined posttransla-
tional modifications such as lysine acetylation and
tyrosine phosphorylation, suggesting metabolic
and signal-dependent regulation of RBP function.
RBDs display a high degree of evolutionary conser-
vation and incidence of Mendelian mutations, sug-
gestive of important functional roles. RBDmap thus
yields profound insights into native protein-RNA in-
teractions in living cells.
INTRODUCTION
RNA metabolism relies on the dynamic interplay of RNAs with
RNA-binding proteins (RBPs) forming ribonucleoprotein com-
plexes, which control RNA fate from synthesis to decay (Glisovic
et al., 2008). Due to their central role in cell biology, it is unsurpris-
ing that mutations in RBPs underlie numerous hereditary dis-
eases (Castello et al., 2013a; Lukong et al., 2008).
Many RBPs are modular, built from a limited pool of RNA-
binding domains (RBDs), including the RNA recognition motif
(RRM) and other canonical RBDs (Lunde et al., 2007). These do-
mains have been characterized biochemically and structurally,
furthering our understanding of protein-RNA interactions. The696 Molecular Cell 63, 696–710, August 18, 2016 ª 2016 The Author
This is an open access article under the CC BY license (http://creativeidentification of unorthodox RBPs lacking canonical RBDs ex-
pands the scope of physiologically important protein-RNA inter-
actions (e.g., Jia et al., 2008).
System-wide approaches to identify RBPs have recently been
developed, including immobilization of RNA probes (Butter et al.,
2009) or proteins (Scherrer et al., 2010; Tsvetanova et al., 2010),
followed by in vitro selection of their interaction partners. These
experiments identified numerous proteins previously unknown
to bind RNA. While informative, in vitro protein-RNA interactions
may arise non-physiologically from the electrostatic properties
of RNA. To address this limitation, in vivo UV crosslinking has
been used to covalently stabilize native protein-RNA interactions
occurring in living cells. After cell lysis, proteins covalently bound
to polyadenylated [poly(A)] RNAs are isolated by oligo(dT) selec-
tion and identified by quantitative mass spectrometry (Baltz
et al., 2012; Castello et al., 2012). This approach (named RNA in-
teractome capture) identified over a thousand RBPs in HeLa and
HEK293 cells, hundreds of which were previously unknown to
bind RNA. Subsequently, similar data sets were obtained from
mouse embryonic stem cells, Saccharomyces cerevisiae, and
Caenorhabditis elegans (Beckmann et al., 2015; Kwon et al.,
2013; Matia-Gonza´lez et al., 2015; Mitchell et al., 2013), confirm-
ing earlier findings and further uncovering the repertoire of RBPs.
Several of the unorthodox RBPs identified in these studies
have been characterized for their physiological roles in RNA
biology. These include metabolic enzymes (Beckmann et al.,
2015), regulators of alternative splicing (Papasaikas et al.,
2015; Tejedor et al., 2015), the E3 ubiquitin ligase TRIM25
(Choudhury et al., 2014), or the FAST kinase domain-containing
protein 2 (FASTKD2) (Popow et al., 2015). However, the RNA-
binding regions of these unorthodox RBPs remain largely
unknown.
To identify the interaction sites of such proteins with RNA, UV
crosslinking followed by extensive RNase treatment has been
used to detect the peptidemass shift induced by the crosslinked
RNA remnant via mass spectrometry (Schmidt et al., 2012).
While conceptually simple, the mass heterogeneity of the nucle-
otide remnant has rendered this approach challenging in prac-
tice. Some RBDs have been characterized in vitro using this
approach (reviewed in Schmidt et al., 2012), and a sophisticated
algorithm allowed assignment of 257 binding sites from 124 pro-
teins in yeast (Kramer et al., 2014). While informative, this data(s). Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
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Figure 1. In Vivo Identification of RBDs by RBDmap
(A) Schematic representation of the RBDmap workflow.
(B) LysC- and ArgC-mediated proteolysis wasmonitored without trypsin treatment. The protease digestion under RBDmap conditions or in buffers typically used
in MS studies (optimal) were compared to in silico digestions defining 0% miscleavage. The missed cleavages were calculated and plotted.
(C) Distribution of MS-identified LysC/ArgC fragments based on their number of amino acids.
(legend continued on next page)
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set is strongly enriched for interactions mediated by RRMs,
because the challenging identification of peptides with aberrant
mass spectra requires both abundance and high crosslinking
efficiency for detection. Nonetheless, 10% of the identified inter-
action sites mapped to non-canonical RBDs, supporting the ex-
istence of unanticipated modes of RNA binding.
Here, we develop and exploit RBDmap as a method for the
in vivo identification of RBDs on a proteome-wide scale. We
identified 1,174 high-confidence RNA-binding sites in 529
RBPs from HeLa cells, generating an unprecedented atlas of
RNA-binding architectures in vivo.
RESULTS AND DISCUSSION
Proteome-wide Mapping of RBDs by RBDmap
To define how RBPs bind to RNA in living cells, we extended
RNA interactome capture (Castello et al., 2013b) by addition of
an analytical protease digestion step followed by a second round
of oligo(dT) capture andmass spectrometry (Figure 1A). First, UV
light is applied to cell monolayers to covalently stabilize native
protein-RNA interactions taking place at ‘‘zero’’ distance (Pa-
shev et al., 1991). While UV exposure using dosages exceeding
those used here can potentially promote protein-protein cross-
linking (Davidenko et al., 2016; Suchanek et al., 2005), we could
not detect such crosslinks under our conditions, evidenced by
the lack of UV-dependent, high molecular weight complexes in
RNase-treated samples (Figures S1A and S4A; Strein et al.,
2014).
Proteins crosslinked to poly(A) RNA are isolated using
oligo(dT) magnetic beads and purified by stringent washes
that include 500 mM LiCl and chaotropic detergents (0.5%
LiDS), efficiently removing non-covalent binders (Castello
et al., 2012, 2013b). After elution, RBPs are proteolytically di-
gested by either LysC or ArgC. These proteases were selected
as best suited for RBDmap by an in silico simulation of their
predicted cleavage patterns of known HeLa RBPs (Castello
et al., 2012) and their compatibility with subsequent tryptic
digestion (Figure S1B). Analysis by mass spectrometry (MS)
of LysC- and ArgC-treated samples revealed an excellent
match with the in silico predictions, as reflected by the low
number of missed cleavages (Figures 1B and 1C). The exten-
sive proteolysis of HeLa RBPs is achieved without compro-
mising RNA integrity (Figures 1D and S1C–S1E). The average
peptide length after LysC and ArgC treatment is 17 amino
acids, which defines the resolution of RBDmap (Figure 1C).
Note that the extensive protease treatment disrupts protein
integrity, and thus protein-protein complexes that might have(D) Silver staining shows the protein pattern of purified RBPs prior to and after L
(E) Scatter plot comparing the peptide intensity ratios between RNA-bound and
(RBDpep) and 10% FDR (candidate RBDpep) are shown in red and salmon, resp
(F) Peptide intensity ratios between LysC and ArgC experiments computed fr
RBDpeps (red), candidate RBDpeps (salmon), and background peptides (gray).
(G) Venn diagram comparing the proteins within the RBDmap data set and the H
(H) Comparison of the peptide intensity ratios from three biological replicates betw
and released fractions (y axis) (color code as above).
(I) Number of proteins harboring recognizable or unknown RBDs in the HeLa mR
See also Table S1 and Figure S1.
698 Molecular Cell 63, 696–710, August 18, 2016withstood the experimental conditions will be released into
the supernatant.
We collected an input sample aliquot after UV irradiation,
oligo(dT) selection, and protease digestion, which in principle
should reflect the RNA interactome (Figure 1A). When compared
to a non-irradiated specificity control, the resulting high-confi-
dence RBPs overlap 82% with the previously published human
RNA interactomes (Baltz et al., 2012; Beckmann et al., 2015;
Castello et al., 2012). This high concordance shows that LysC
and ArgC treatments are fully compatible with the RNA interac-
tome capture protocol. The remaining two thirds of the LysC or
ArgC-treated samples were subjected to a second round of
oligo(dT) purification leading to two peptide pools (Figure 1A):
(1) peptides released from the RNA into the supernatant, and
(2) peptides remaining covalently bound to the RNA, represent-
ing the RNA-binding sites of the respective RBPs. Importantly,
subsequent tryptic digestion of the RNA-bound LysC/ArgC frag-
ments yields two classes of peptides: the portion that still re-
mains crosslinked to the RNA (X-link) and its neighboring pep-
tides (N-link) (Figure 1A). While the directly crosslinked
peptides (X-link) are difficult to identify due to the heterogeneous
mass shift induced by the residual nucleotides (Kramer et al.,
2014; Schmidt et al., 2012), the native peptides adjacent to the
crosslinking site (N-link) can be identified by standard MS and
peptide search algorithms. The original RNA-bound region of
the RBP (i.e., RBDpep; Figure 1A), which includes both the
crosslinked peptide (X-link) and its unmodified neighboring
peptides (N-link), is then re-derived in silico by extending the
MS-identified peptides to the two nearest LysC or ArgC cleavage
sites.
Analysis of the RNA-bound and released fractions by quantita-
tive proteomics shows high correlation of the resulting peptide
intensity ratios between independent biological replicates.
These ratios follow a bimodal distribution with one mode repre-
senting the released peptides (gray) and the other the RNA-
bound ones (red; Figures 1E and S1F). We detected 909 and
471 unique N-link peptides as significantly enriched in the
RNA-bound fractions of LysC- or ArgC samples, respectively
(1% false discovery rate, FDR) (Figure S1G). Notably, computed
RNA-bound/released peptide intensity ratios also correlate be-
tween the LysC and ArgC data sets (Figure 1F), supporting the
robustness of the workflow. Due to their different specificities,
each protease also contributes unique 1% FDR RBDpeps to
the complete peptide superset (Figure S1G), covering 529
RBPs that highly overlap with human RNA interactomes (Fig-
ure 1G) (Baltz et al., 2012; Beckmann et al., 2015; Castello
et al., 2012). Proteins within the RBDmap data set range fromysC treatment (crosslinking: CL).
released fractions. The peptides enriched in the RNA-bound fraction at 1%
ectively (Pearson correlation coefficient: r).
om three biological replicates. The dots represent released peptides (blue),
eLa, HEK293, and Huh-7 RNA interactomes.
een UV-irradiated and non-irradiated inputs (x axis) and between RNA-bound
NA interactome (left) and in RBDmap dataset (right).
low to high abundance (Figure S1H), following a similar distribu-
tion as the input fraction and theHeLaRNA interactome (Castello
et al., 2012). Thus, RBDmap is not selective for highly abundant
proteins. There were 154 additional RBPs that were identified
here, helped by the reduction of sample complexity and of
experimental noise by the additional proteolytic step and the
second oligo(dT) capture. In agreement with this explanation,
the relative abundance of corresponding RBDpeps is higher in
the RNA-bound fractions than in the ‘‘input’’ samples (Figures
1H and S1I). Thus, RBDmap detects RNA-binding regions within
hundreds of RBPs in one approach, even if it does not cover all
RBPs identified by RNA interactome capture (Figure 1G).
Proteins will be missed by RBDmap when (1) binding to non-
polyadenylated RNAs, (2) displaying low crosslinking efficiency,
(3) interacting with the phospho-sugar backbone, but not the
nucleotide bases, or (4) lacking suitable cleavage sites for trypsin
within the LysC and ArgC proteolytic fragments and hence lack-
ingMS-identifiable N-link peptides. Thus, the distribution of argi-
nines (R) and lysines (K) will influence whether a given RBP can
be studied by RBDmap, and we used two different proteases
to maximize the identification of RBDpeps.
About half of the RBPs covered by RBDpeps harbor well-es-
tablished RBDs and play known functions in RNA biology, re-
flected by a strong and significant enrichment of RNA-related
protein domains and biological processes comparable to the
HeLa RNA interactome (Figures 1I and S1J). Note that the
reduced RBP coverage of RBDmap compared to RNA interac-
tome capture equally affects both well-established and unortho-
dox RBPs (Figures 1I and S1J).
RBDmap ‘‘Rediscovers’’ Classic RBDs
Interestingly, RNA-bound and released proteolytic fragments
display distinct chemical properties. Released peptides are
rich in negatively charged and aliphatic residues, which are
generally underrepresented in RNA-binding protein surfaces
(Figures 2A, 2B, and S2A). Conversely, RBDpeps are signifi-
cantly enriched in amino acids typically involved in protein-
RNA interactions, including positively charged and aromatic
residues. These data show that the chemical properties of the
RBDpeps resemble those expected of bona fide RNA-binding
surfaces. As a notable exception, glycine (G) is enriched in
RBDpeps, but depleted from protein-RNA interfaces derived
from available structures (Figures 2A and 2B). Flexible glycine
tracks can contribute to RNA binding via shape-complemen-
tarity interactions as described for RGG boxes (Phan et al.,
2011). Hence, lack of glycine at binding sites of protein-RNA
co-structures reflects the technical limitations of crystallo-
graphic studies regarding disordered protein segments.
Validating the RBDmap data, classical RBDs such as RRM,
KH, cold shock domain (CSD), and Zinc finger CCHC, are
strongly enriched in the RNA-bound fraction (Figure 2C). This
enrichment can also be appreciated at the level of individual pro-
teinmaps (Figures 2D and S2B–S2D). To evaluate the capacity of
RBDmap to identify bona fide RBDs, we focused on RBPs that
harbor at least one classical RBD (as listed in Lunde et al.,
2007). MS-identified peptides from these proteins were classi-
fied as ‘‘within’’ or ‘‘outside’’ a classical RBD, according to their
position within the proteins’ architecture (Figure 2E). The relativefraction of peptides within versus outside of the RBD was then
plotted for each possible RNA-bound/released intensity ratio
(Figure 2F). Correct re-identification of classical RBDs would
lead to an ascending line (i.e., within/outside ratios should
grow in parallel to the RNA-bound/release ratios; Figure 2E),
while a random distribution of peptides within and outside of
classical RBDs would yield a horizontal line (i.e., within/outside
ratios do not vary in accordance with the RNA-bound/released
ratios; Figure 2E). As shown in Figure 2F, the relative fraction
of peptides mapping within classical RBDs increases in parallel
with the RNA-bound/released ratios. Thus, RBDmap correctly
assigns RNA-binding activity to well-established RBDs.
Unexpected initially, helicase domains are underrepresented
in the RNA-bound fraction (Figure 2C). However, the high num-
ber of released helicase peptides likely reflects (1) the transitory
and dynamic interactions that helicases establish with RNA,
(2) the large protein segments of the domain situated far from
the RNA, and (3) the predominance of interactions with the phos-
pho-sugar backbone over nucleotide bases (Figures S2C–S2E)
(Bono et al., 2006). Nevertheless, high-confidence RBDpeps
are found at the exit of the helicase tunnel, as discussed below
(Figures S2C–S2E).
High-Resolution Determination of RNA-Binding Sites
For direct validation of the RBDmap data, we selected all those
RBPs for which protein-RNA co-structures are available within
the Protein Data Bank (PDB) repository. These were ‘‘digested’’
in silico with either LysC or ArgC, and the predicted proteolytic
fragments were considered as ‘‘proximal’’ to RNA when the dis-
tance to the closest RNA molecule is 4.3 A˚ or less; otherwise,
they were categorized as non-proximal (Figure 3A). About half
of all LysC and ArgC fragments are proximal to RNA by this cri-
terion, reflecting that many RBP structures are incomplete and
focused on the RBDs (average protein coverage 50%). By
contrast, 70.3% (LysC) and 81% (ArgC), respectively, of
RBDpeps qualify as proximal, showing that RBPmap highly
significantly enriches for peptides in close proximity to the
RNA (Figure 3A). Several factors suggest that the pool of pep-
tides classified as proximal in the analyzed structures even
underestimates the performance of RBDmap: (1) in several
structures of RBPs that harbor two or more RBDs, only one of
the RBDs displays the interaction with RNA (e.g., PDB 3NNC)
(Teplova et al., 2010). At least in some of these cases, structures
lack RNA contacts of RBDs that likely occur in vivo. (2) Proteins
are normally co-crystallizedwith short nucleic acids (5 to 8 nucle-
otides), and their physiological RNA partners likely establish
additional interactions with the RBP. (3) RNA-protein co-struc-
tures usually reflect one interaction state, while protein-RNA in-
teractions are typically more dynamic in vivo (Ozgur et al.,
2015; Safaee et al., 2012).
RBDmap also correctly assigns RNA-binding regions within
large protein complexes such as the nuclear cap-binding com-
plex. The small nuclear cap-binding protein (NCBP) 2 (or
CBP20) directly contacts mRNA via the cap structure
(m7GpppG), while the larger NCBP1 (CBP80) interacts with
NCBP2 (Mazza et al., 2002). In agreement, RBDmap defines
the RNA-binding region of NCBP2 within the m7GpppG-binding
pocket and no RBDpep is assigned to the large NCBP1Molecular Cell 63, 696–710, August 18, 2016 699
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Figure 2. Identification of Well-Established RBDs by RBDmap
(A) Amino acid enrichment within RBDpeps (salmon) over released (blue) proteolytic fragments (*, 10% FDR and **, 1% FDR).
(B) Amino acid enrichment within RNA-binding protein surfaces (%4.3 A˚ to the RNA) over distant regions (>4.3 A˚ from the RNA) extracted from protein-RNA
co-structures.
(C) Bar plot showing the odds ratio of the most enriched known RBDs.
(D) Distribution of RBDpeps and released fragments in a classical RBP. The x axis represents the protein sequence fromN to C terminus, and the y axis shows the
RNA-bound/released peptide intensity ratios. The protein domains are shown in boxes under the x axis (LysC: L and ArgC: A).
(E) Schematic representation of RBDpeps mapping within or outside of classical RBDs (left). The idealized outcome of a perfect correlation between RBDpeps
and classical RBDs (top right) and random distribution are shown (bottom right).
(F) Computed ratio of peptides mapping within known RBDs versus outside RBDs, regarding their peptide RNA-bound to released ratios. The horizontal line
represents the baseline for uncorrelated data (i.e., the proportion of peptides mapping to classical RBD in the whole validation set in absence of enrichment; see
E bottom).
See also Table S2 and Figure S2.(Figure S3A). Moreover, RBDmap defines the corresponding
RNA-binding sites within NCBP2 (Mazza et al., 2002) and its
cytoplasmic counterpart eIF4E (Brown et al., 2007) (Figure S3B),
in spite of their low sequence identity. The glutamyl-prolyl-tRNA
synthetase (EPRS) represents a large non-canonical RBP that
harbors two tRNA synthase domains separated by three
WHEP motifs (Figures S3C and S3D). The first and second700 Molecular Cell 63, 696–710, August 18, 2016WHEP motif bind the GAIT RNA element present in the
30 UTRs of a number of pro-inflammatory mRNAs (Jia et al.,
2008), in complete agreement with the RBDmap data.
To test whether RNA-binding assignments of RBDmap can
reach near single-amino acid resolution, we collected the com-
plete set of RBDpeps and released peptides mapping to a given
RBD class (e.g., RRM) and assessed their relative position within
A B
C E
D F
G H
I J
Figure 3. RBDmap Identifies RNA-Binding Regions with High Accuracy
(A) Schematic representation of proximal and non-proximal peptides (left). The proteins within protein-RNA co-structures were digested in silico with LysC or
ArgC and predicted fragments aligned with the RBDpep supersets. The left bars represent the proportion of proximal and non-proximal LysC/ArgC fragments in
the complete structure superset (random probability). The right bars show the % of aligned RBDpeps that are RNA proximal or non-proximal (***p < 0.001).
(legend continued on next page)
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the domain (from 0 to 1) aswell as its adjacent upstream (from1
to 0) and downstream regions (from 1 to 2) (Figure 3B). The MS-
identified part (N-link) of each RBDpep was then subtracted to
infer the RNA-crosslinked (X-link) moiety(s), which cannot be
identified by conventional MS due to their nucleotide remnant
(Figures 1A and 3B). The X-link/released peptide ratio was calcu-
lated for each position in the domain, where high prevalence of
X-link over released peptides will indicate RNA binding (Fig-
ure 3B). The high accuracy of this analysis is illustrated by the
example profile obtained for RRMs. As shown in Figures 3C,
3D, and S3E, the highest X-link/released peptide ratio points to
b strand 1, 2, and 3 as partners in the interaction with RNA, in
agreement with the dozens of RNA-RRM co-structures avail-
able. Note that the LysC and ArgC proteases dissected the
RRM in a differential manner: while LysC points to b strand 1
and 3, ArgC identifies b strand 2 as RNA-binding site, reflecting
that the mapping capacity by these proteases depends on the
distribution of lysines and arginines. Moreover, these data sup-
port the complementarity of the LysC and ArgC data sets to build
accurate and comprehensive RNA-binding maps. Unexpect-
edly, we observed two discrete peaks of high X-link/released
peptide ratio within the a helices placed at the back of the
RRM. These peaks coincide with amino acids projected from
the a helix to the RNA in several structures (Figure S3F) (Safaee
et al., 2012; Teplova et al., 2010) and hence confirm the accuracy
of RBDmap.
This analysis also successfully assigned correct RNA-binding
sites to KH, DEAD-box helicase, and CSD, as shown in Figures
3E–3J, S3G, and S3H. The DEAD box helicase domain estab-
lishes interactions primarily with the phospho-sugar backbone
of the RNA, while nucleotide bases project away from the protein
core (Figure S3I). X-link peptide coverage of RBDmap for the
DEADbox domain identifies one alpha helix in the helicase tunnel
exit that coincides with the only position in RNA-protein co-crys-
tals where multiple amino acids establish direct contacts with
nucleotide bases. Interestingly, different binding orientations of
the double-stranded RNA-binding motif (DSRM) have been
observed in structural studies (Figure S3J) (Fu and Yuan, 2013;
Ramos et al., 2000). The X-link peptide coverage analysis of
the DSRM domain highlights the loop separating the second
and third b strands as interaction partners with the double-
stranded RNA (Figures S3J and S3K). Note that this loop is
shown in several RNA-protein co-structures to be projected
into theminor grove of the double-stranded RNA helix, establish-
ing numerous interactions with the Watson-Crick paired bases
(Lunde et al., 2007). In summary, RBDmap faithfully re-identifies(B) Schematic representation of the X-link peptide coverage analysis.
(C) x axis represents the relative position of the RRM (from 0 to 1) and their upstream
peptides at each position of the RRM and surrounding regions using the LysC dat
the RRM and flanking regions is shown (bottom).
(D) The ratio of X-link over released peptides was plotted in a representative RR
(E) As in (C), but for the DEAD-box domain.
(F) As in (D), but using the PDB 2J0S as a DEAD-box helicase model.
(G) As in (C), but for the KH domain.
(H) As in (D), but using the PDB 4B8T as a model for a KH domain.
(I) As in (C), but for the CSD.
(J) As in (D), but with the PDB 3TS2 as a model for a CSD.
See also Table S2 and Figure S3.
702 Molecular Cell 63, 696–710, August 18, 2016the protein surfaces of canonical RBDs that contact nucleotide
bases.
Identification of Non-canonical RBDs
For more than half of the RBPs characterized by RBDmap,
no functional or domain annotation related to RNA biology is
currently available (Figures 1I and S1J). RBDpeps identify
dozens of unorthodox globular RBDs associated with different
molecular functions, including DNA binding, enzymatic cores,
mediators of protein-protein interactions, or of protein localiza-
tion (Figure 4A; Table S2). As an illustrative example, thioredoxin
(TXN) catalyzes disulfide bond formation and has recently been
discovered in RNA interactomes (Beckmann et al., 2015;
Castello et al., 2012). RBDmap identifies an RBDpep at the N ter-
minus of TXN (Figure 4B; Table S1) that overlaps with two sol-
vent-exposed lysines (K3 and 8) highlighted as potential binding
sites in the X-link coverage analysis for the TXN fold (Figures 4B
and 4C). To evaluate this assignment functionally, we expressed
TXN-eGFP fusion proteins in HeLa cells. Following in vivo UV
crosslinking, oligo(dT) capture, and stringent washes, green
fluorescence in eluates was measured to quantify RNA binding
(Figure 4D) (Castello et al., 2013b; Strein et al., 2014). We used
unfused eGFP as negative control and the well-established
RNA-binding helicase MOV10 as a positive control for RNA
binding (Gregersen et al., 2014). Although all the fusion proteins
are expressed at similar levels in cells, only TXN-eGFP and
MOV10-YFP co-purify with poly(A) RNAs significantly above
background (Figure 4E). Mutation of K3 and/or K8 to glutamic
acid (E) totally abrogates TXN RNA-binding activity. Conversely,
conservative mutation to arginine (R) is tolerated. These results
experimentally validate the accurate identification of a previously
unknown RNA-binding region by RBDmap.
We also noticed clusters of RBDpeps within enzymes. Pep-
tidyl prolyl cis/trans isomerases are classified based on their
domain architecture into two groups: PPI and FKBP. This pro-
tein superfamily has close links to RNA metabolism, and two
members, PPIE and PPIL4, harbor classical RRMs (Mesa
et al., 2008). However, RNA interactome studies found 11
additional members of this family that lack RRMs as RBPs,
suggesting the existence of a still unknown mechanism of
RNA binding (Castello et al., 2012). RBDmap reveals this
RNA-binding activity within both the PPI and FKBP folds
(Tables S1 and S2). Although lacking sufficient peptide
coverage to perform an X-link peptide analysis, we noticed
two clusters of RBDpeps at the N- and C-termini of the FKBP
fold that are located far apart in primary sequence, but close(1 to 0) and downstream (1 to 2) regions. The ratio of the X-link over released
a set was plotted (top). The secondary structure prediction for each position of
M-RNA structural model (PDB 2FY1) using a heatmap color code.
AF
G
J K
I
H
B
D E
C
(legend on next page)
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in 3D structure (Figures S4B and S4C). The mapped candidate
RBD opposes the catalytic site.
Furthermore, we noticed clusters of RBDpeps in six chaper-
ones of the heat shock protein (HSP) 90 and 70 families (Fig-
ure S4D). HSPs are induced by cellular stress and prevent
protein misfolding and subsequent aggregation, which typically
occur in disordered regions of RBPs in health and disease
(Weber and Brangwynne, 2012). Indeed, HSPs have been func-
tionally linked to RNA metabolism and translation (Iwasaki et al.,
2010; Willmund et al., 2013). Chaperone domain binding to RNA
may help to increase the local concentration of the chaperone
machinery at ribonucleoprotein complexes to avoid the accumu-
lation of pathological aggregates.
Apparently, numerous enzymes of intermediary metabolism
bind RNA through regions in close proximity to their substrate-
binding pockets. Specifically, the di-nucleotide binding domain
(or Rossmann fold) and mono-nucleotide binding folds emerge
as bona fide RBDs with 12 proteins mapped by RBDmap (Table
S3), extending earlier observations (Ciesla, 2006; Nagy and
Rigby, 1995). RBDpeps mapping to Aldolase (ALDO) A and C
delimit the fructose 1,6 bisphosphate interacting domain (Fig-
ures S4E and S4F), suggesting that RNA and metabolite may
compete for this binding pocket. Overall, the RBDpeps identified
within metabolic enzymes show that the few well-characterized
examples such as aconitase 1 (iron regulatory protein 1, IRP1),
glyceraldehyde-3-phophate dehydrogenase, and thymidylate
synthase may represent the tip of the iceberg of a more general
engagement of metabolic enzymes with RNA (reviewed in Cas-
tello et al., 2015).
RBDmap also uncovers RNA-binding activities within PDZ,
14-3-3, ERM, and the tubulin-binding domains, which are
involved in protein-protein interactions and protein localization
(Figures 4F, 4G, and S4G–S4I). Due to the high peptide coverage
of the PDZ domain, we could generate an X-link analysis (Figures
4F and 4G). This map shows a discrete RNA-binding site within a
basic cavity formed by a short a helix and two b strands.
RBDmap also identifies RNA-binding sites within domains of
unknown function such as NDR and DZF. N-myc downstream-
regulated genes (NDRGs) represent a family of proteins with
unknown function. NDRG1 is a metastasis suppressor relevant
for cancer progression and prognosis (Chang et al., 2014), its
exact molecular function has remained unknown. RBDmap re-
solves a conserved RNA-binding region within the NDR domain
of NDRG1, NDRG2, and NDRG4. RBDpeps reproducibly mapFigure 4. Globular RBDs Discovered by RBDmap
(A) Odds ratios for the most highly enriched RBDs.
(B) RBDpep and released peptidesmapping to TXN as in Figure 2D (top). The ratio
in Figure 3C is shown (middle). The secondary structure prediction for each posi
(C) Crystal structure of human TXN (PDB 3M9J), K3 and K8 are highlighted, and
(D) Schematic representation of the protocol for measurement of RNA-binding u
(E) Relative total (input) or RNA-bound (eluate) green fluorescence signal from ce
(F) As in (B), but for PDZ domain.
(G) Ratio of X-link over released peptides plotted as a heatmap in a PDZ homolo
(H) As in (B), but for DZF domain.
(I) As in (G), but using a DZF homology model.
(J) Autoradiography of FLAG-HA tagged proteins after PNK assay.
(K) Western blotting using an antibody against the HA tag. The polypeptides of t
See also Tables S2, S3, and S5 and Figure S4.
704 Molecular Cell 63, 696–710, August 18, 2016to the helix-loop-b strand structure at the C terminus of the
NDR fold (Figures S4J and S4K). DZF is predicted to harbor nu-
cleotidyltransferase activity (Kuchta et al., 2009) and to pro-
mote protein dimerization (Wolkowicz and Cook, 2012). The
X-link peptide coverage analysis maps the RNA-binding region
to a deep, basic cleft between two symmetrical domain sub-
units (Figures 4H and 4I). The RNA-binding activity of the DZF
domain is compatible with its proposed nucleotidyltransferase
function.
To independently assess RNA-binding of PDZ and DZF do-
mains, we used the T4 polynucleotide kinase (PNK) assay as
an orthogonal approach. In brief, cells are irradiated with UV light
and, after lysis, RNA is trimmed with RNase I. Proteins of interest
are immunoprecipitated under stringent conditions and the pres-
ence of RNA revealed by 50 end phosphorylation with PNK and
[g-32P]-ATP, followed by SDS-PAGE and autoradiography. We
generated Tet-inducible HeLa cell lines expressing the PDZ
domain of b-1-syntrophin (SNTB) 1 and SNTB2, as well as the
DZF domains of Zinc finger RNA-binding protein (ZFR) and inter-
leukin enhancer-binding factor (ILF) 2 and ILF3, all fused to a
FLAG-HA tag. As positive controls, we used the full-length
ILF3 (FL), its DSRM domain alone, and hnRNPC, while actin
(ACTB) was used as a negative control. The PNK assay shows
radioactive bands of the expected molecular weight for all
tagged PDZ and DFZ domains and only when UV light was
applied to the cultured cells (Figures 4J and 4K). By contrast,
no signal is detectable for the control ACTB. As expected, the
DSRM domain of ILF3 also displays RNA-binding activity. Taken
together, these data corroborate the RBDmap assignment of
PDZ and DZF domains as RBDs.
Even if functional studies will have to define the physiological
roles of these unconventional RBDs in the future, their biological
relevance warrants consideration. It is possible that these RBDs
may endow RBPs with ‘‘moonlighting’’ activities in posttran-
scriptional regulation, akin to cytosolic aconitase (IRP1) (Muck-
enthaler et al., 2008). Alternatively, the RBDs could serve as
‘‘docking sites’’ for regulatory or scaffolding RNAs that inhibit,
activate, or modify protein functions. In analogy, innate immune
effectors such as PKR, TLR3, TLR7, TLR8, or RIG-I, can be
controlled by pathogen-derived RNAs (Barbalat et al., 2011; Yu
and Levine, 2011). RNA may also serve to recruit proteins to
RNPs, akin to NEAT1 RNA in paraspeckle formation (Clemson
et al., 2009). The identification of these RBDs and the mapping
of the RNA-interaction sites for hundreds of proteins serve as aof the X-link over released peptide coverage at each position of the TXN fold as
tion of the TXN fold and flanking regions is shown (bottom).
the identified RBDpep is shown in red.
sing eGFP fusion proteins.
lls expressing different eGFP fusion proteins (***p < 0.01, t test, and n = 9).
gy model.
he expected molecular masses are indicated by asterisks.
critical step toward definition of the biological functions of these
RBPs in detail.
Disordered Regions Emerge as Frequent RNA
Interaction Sites In Vivo
A high proportion of the human RBPs lack native 3D structure
(Castello et al., 2012), and these disordered regions can occa-
sionally engage in non-canonical protein-RNA interactions (45
examples reviewed in Ja¨rvelin et al., 2016). In some instances,
these interactions can induce co-folding of both molecules
(Phan et al., 2011). While this mode of interaction emerged
recently, the scope of disorderedmotifs involved in RNA-binding
remained unknown. Strikingly, half of the RBDpepsmap to disor-
dered regions, and RBDmap identifies a disordered RBD as the
sole detectable RNA-binding site for 170 RBPs (Figures 5A 5B,,
and S5A). Disordered RBDpeps largely mirror the chemical
properties of the whole RBDpep superset, apart from the ex-
pected enrichment for disorder-promoting residues (proline [P],
serine [S], and glycine [G]), as well as R and glutamine (Q) (Fig-
ures 5C and S5B).
Detailed analysis identifies clusters of disordered RBDpeps
that can be classified on the basis of sequence motifs. While a
few R-rich, RGG, and SR repeats have previously been shown
to bind RNA experimentally (Ja¨rvelin et al., 2016), RBDmap ex-
pands the RNA-binding role of these motifs by dozens of
additional examples (Figures 5D and S5C). The superset of
RNA-binding RGG boxes can be subclassified by the lengths
of the glycine linkers (Thandapani et al., 2013). Because glycines
can position arginines and contribute to RNA binding providing
shape complementarity, G-linker length could serve in setting
the motif’s specificity for RNA. In agreement, both arginine and
glycine substitutions impair RGG-RNA recognition (Phan et al.,
2011).
Aromatic residues are typically found in hydrophobic cores.
However, histidines (H), phenylalanines (F), and especially tyro-
sines (Y) occur within the RNA-binding disordered regions (Fig-
ures 5D and S5C). YGG repeats (also called [G/S]Y[G/S]) can
promote protein aggregation in vitro, inducing hydrogel forma-
tion and amyloid-like fibers, as well as dynamic phase transi-
tions in vivo (Han et al., 2012; Kato et al., 2012). Since YGG
repeats are identified as a potential RNA-binding motif in our
data set, it will be important to elucidate whether their RNA-
binding capacity is affected by the aggregation state and,
conversely, whether RNA-binding to such disordered linear
motifs can affect phase transitions and granule formation
(Zhang et al., 2015).
Lysine (K) combines with negatively charged residues, G, P, or
Q, to form distinctive RNA-binding motifs (Figures 5D and S5C).
The stoichiometry and distances between lysines and other
amino acids are similar across analogous K-rich motifs present
in non-homologous proteins (Figure 5E). Several copies of a
repeat combining basic and acidic residues within the neuro-
blast differentiation-associated protein AHNAK are identified
by RBDmap (Figure S5D), suggesting that low complexity re-
gions can contribute to modular RNA-binding architectures,
similar to globular RBDs. Interestingly, the K-rich regions within
RBPs display similarities with the basic tails of DNA-binding pro-
teins. The large capture radius of these disordered regions playimportant roles in transcription factor activity by favoring ‘‘hop-
ping’’ and ‘‘sliding’’ over 3D diffusion to reach their target
sequences (Vuzman et al., 2010). K-rich sequences may play
similar roles in RBPs.
To validate the disordered regions identified by RBDmap as
bona fide RNA-binding motifs, we fused the RGG-rich and the
K-rich sequences from FUS and Methyl-CpG-binding protein 2
(MECP2), respectively, to eGFP and tested the fusion proteins
with the same assay as in Figure 4D: both short motifs suffice
to confer RNA-binding to eGFP (Figures 5F and 5G).
The biological function and mode of interaction of disordered
regions with RNA should be further investigated.
Uncovering Biological Properties of RBDs
Previously unknown RNA-binding globular and disordered re-
gions display similar mean isoelectric points as known RBDs
(Figure 6A), while their released counterparts exhibit a signifi-
cantly lower isoelectric point, as expected. Thus, (1) both previ-
ously unknown and well-characterized RBDs share common
chemical properties, (2) they differ from released fragments,
and (3) the unorthodox RBDs do not artificially associate with
RNA due to an abnormally high isoelectric point. Established
RBPs and proteins harboring previously unknown globular and
disordered RBDs display very similar mRNA abundance profiles,
ranging from low to high levels, with a slight tendency to lower
abundance for the unconventional folded and disordered RNA-
binding regions (Figures 6B and 6C). Thus, proteins with unor-
thodox RBDs are not biased toward high abundance. Notably,
RBDpeps in both globular and disordered RBDs are more highly
conserved throughout evolution than their released counterparts
(Figure 6D), suggesting functional relevance.
Cross-referencing of the RBDpep data sets with databases of
curated posttranslational modifications shows that RNA-binding
sites represent hot spots for defined post-translational modifica-
tions (PTMs, p = 2.0253 1008), including tyrosine phosphoryla-
tion, methylation, acetylation, and malonylation (Figure 6E). This
finding suggests that, reminiscent of chromatin remodeling,
RBDs are posttranslationally regulated and respond to signaling
and metabolic cues. The conserved amino acid contexts of
these PTMs implicate sequence-selective modifying enzymes
(Figure 6F). Interestingly, acetylation frequently occurs in a lysine
two positions upstream of a conserved proline (Figure 6F). Pro-
line isomerization in the basic tail of histone H3 is regulated by
acetylation of adjacent lysines and has notable consequences
for protein conformation (Howe et al., 2014). Our results suggest
the possibility that this regulatory mechanism could also apply to
RBP regulation.
Our data also show that Mendelian disease mutations cluster
within RBDs compared to natural variants (p = 0.0001796) (Fig-
ure 6G; Table S4). For example, one RBDpep maps to an
RGG-box in FUS that is a hotspot for disease-associated
mutations (Figure 6H) (Shang and Huang, 2016), and the RNA-
binding activity of this region is validated here by an orthogonal
approach (Figures 4D and 5G). Interestingly, a mutation in
this region (R495X) causes amyotrophic lateral sclerosis (ALS)
and correlates with impaired interaction of FUS with the SMN
complex and reduced localization to nuclear gems (Yamazaki
et al., 2012). The relationship between altered RNA-bindingMolecular Cell 63, 696–710, August 18, 2016 705
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Figure 5. Disordered Protein Regions as RBDs
(A) Number of RBDpeps mapping to globular and disordered domains.
(B) Number of proteins mapped by at least one RBDpep solely in globular domains, in globular and disordered domains, or only in disordered motifs.
(C) Amino acid enrichment between globular (violet) and disordered (pink) RBDs (*, 10% FDR and **, 1% FDR).
(D) Multiple sequence alignment of short, disordered RBDpeps with clustal omega. The sequence logos were extracted from aligned disordered fragments.
(E) Examples of alignment of K-rich protein motifs.
(F) Disordered RNA-binding motifs from FUS and MECP2 expressed as eGFP fusion.
(G) Relative total (input) or RNA-bound (eluate) green fluorescence signal from cells expressing FUS449–518-eGFP, MECP2267–316-eGFP, or unfused eGFP as a
negative control (**p < 0.01, t test, and n = 6).
See also Figure S5.and disease phenotypes in this and other proteins deserves
further exploration.
Conclusions
RBDmap provides an unprecedented identification of RNA-
binding regions of RBPs in living cells. It describes 1,174 high706 Molecular Cell 63, 696–710, August 18, 2016confidence (1% FDR) RNA-binding sites within 529 proteins.
These sites have been validated as a whole by stringent statisti-
cal analyses (Figure 1) and cross-correlation with well-estab-
lished RBPs and domains, previously studied by biochemical
and structural means (Figures 2 and 3). We also validated a small
number of previously unknown RBDs (TXN, PDZ, DZF, and the
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Figure 6. Features of Known and Previously Unknown RBDs
(A) Dots show the mean isoelectric point of all LysC and ArgC fragments (the bars represent SEM) (***p < 0.01 and not statistically significant: n.s.).
(B) Density plot comparing mRNA abundances of known RBPs and previously unknown globular and disordered RBPs.
(C) Dots show the mean of the mRNA abundance of the protein groups described in (B) (*p < 0.05 and not statistically significant: n.s.).
(D) Bar plot showing the conservation of RBDpeps and released fragments using Homo sapiens as reference (*p < 0.05 and **p < 0.01).
(E) Odds ratios for the most enriched PTMs in RBDpeps versus released fragments.
(F) Sequence logos of conserved amino acids around posttranslational modifications. A position weight matrix is computed from all 12-mer sequences around
the modified residue (10% FDR amino acids are shown).
(G) Bar plot showing the odds ratio of Mendelian mutations occurring in RNA-bound over released fragments.
(H) RBDmap of FUS. The position of the disease-associated mutations is represented as red or blue colored circles if mapping within or outside an RBDpep,
respectively.
See also Table S4.
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disordered regions of MECP2 and FUS) individually, applying
orthogonal methods (Figures 4 and 5). Against this background,
we recommend similar validation experiments for any individual
RBD of interest before further in depth analyses.
Our data suggest that multifunctional globular domains, which
combine RNA-binding with enzymatic functions or protein-pro-
tein interaction surfaces, are commonplace, not rare exceptions.
These invoke additional functions for RNA, including the (allo-
steric or competitive) control of catalytic activities and of
protein-protein interactions. Moreover, disordered regions are
found to play common roles in native protein-RNA interactions,
comprising half of the total RNA-binding sites identified.
The RNA-binding motifs identified here share physico-chemi-
cal features of well-established RBDs, are conserved across
evolution, and represent hot spots for posttranslational modifi-
cations and disease-associated mutations. Individually and in
combination, these features suggest important biological roles.
As a method, RBDmap can now be applied to other cell
types and organisms such as S. cerevisiae, Caenorhabditis
elegans, or Drosophila melanogaster to study the evolution of
RBDs. It can also be applied to cells subjected to different
experimental conditions to investigate the responses of RBPs
to physiological cues such as e.g., stress, starvation, or
differentiation.
EXPERIMENTAL PROCEDURES
RBDmap
Initial UV crosslinking and oligo(dT) purification followed the mRNA interac-
tome capture protocol (Castello et al., 2013b). Complete proteolytic digestions
were performed with LysC or ArgC for 8 hr at 37C. Polyadenylated RNA and
crosslinked peptides were diluted in 20 mM Tris-HCl, 500 mM LiCl, 1 mMDTT,
and 0.5 mM EDTA and recaptured on oligo(dT) beads. The supernatant was
processed forMS (released peptides). oligo(dT) beadswere washed as in Cas-
tello et al. (2013b). All fractions were treated with trypsin and labeled with sta-
ble isotopes in vitro (Boersema et al., 2008). Peptides were analyzed on a liquid
chromatography-tandemMS (LC-MS/MS) platform. The R-scripts used for the
analyses can be found in the R/Bioconductor data-package RBDmapHeLa
(http://www.bioconductor.org). RBDmap data can be accessed under http://
www-huber.embl.de/users/befische/RBDmap.
MS, Protein Identification, and Quantification
Proteins were processed following standard protocols, and the resulting pep-
tides were labeled with stable isotopes in vitro, fractionated, and analyzed on a
nano-HPLC system (Proxeon) or nano-Acquity UPLC system (Waters) coupled
directly to an LTQ Orbitrap Velos (Thermo Fisher Scientific).
Data Analysis
A complete description of data analysis can be found in the Supplemental
Information.
Fluorescence-Based Method to Measure RNA-Binding In Vivo and
PNK Assay
Tet-on HeLa cells expressing eGFP fusion proteins were generated as
described elsewhere (Castello et al., 2012). Upon induction, cells were UV irra-
diated and subjected to small scale RNA interactome capture (Castello et al.,
2013b). Eluates were measured in a plate reader. For PNK assays, cell mono-
layers were irradiated with 150mJ/cm2UV254 (Castello et al., 2013b). After cell
lysis and RNase treatment, FLAG-HA tagged proteins were immunoprecipi-
tated with an anti-FLAG antibody coupled to magnetic beads (M8823, Sigma
Aldrich) and processed as in Beckmann et al. (2015). More detailed information
can be found in the Supplemental Information.708 Molecular Cell 63, 696–710, August 18, 2016ACCESSION NUMBERS
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